Should all patients with SCLC receive prophylactic cranial irradiation if they have responded to treatment? The time has come to improve on a former standard.
Publication/Presentation Date
11-1-2015
Abstract
Brain metastases are common in patients with small cell lung cancer (SCLC), and prophylactic cranial irradiation (PCI) has been shown to reduce the risk of brain metastases in these patients. But how great are the benefits, and do the benefits outweigh the toxicity? In this month's Counterpoints, Dr Ben J. Slotman makes the case for the use of PCI in nearly all patients with SCLC who have responded to treatment, whereas Jacob Yousef and Dr Henry Wagner argue that the role of PCI should be reassessed.
Volume
13
Issue
11
First Page
732
Last Page
733
ISSN
1543-0790
Published In/Presented At
Yousef, J., & Wagner, H. (2015). Should all patients with SCLC receive prophylactic cranial irradiation if they have responded to treatment? The time has come to improve on a former standard. Clinical advances in hematology & oncology : H&O, 13(11), 729–733.
Disciplines
Medicine and Health Sciences
PubMedID
27058697
Department(s)
Fellows and Residents
Document Type
Article